 | |
| Company type | Public company |
|---|---|
| |
| Founded | 2001 in Australia |
| Headquarters | Sydney , Australia |
Areas served | Australia |
Key people | Michael Kavanaugh (CEO, President and Managing Director) Maurie Stang (Chairman) |
| Revenue |  A$100 million (2020)[1] (2020) |
 A$10 million (2020)[1] | |
| Total assets | A$147 million (2020)[1] (2020) |
Number of employees | 311 [1] (2020) |
| Website | www |
Nanosonics is a ASX-listed company in the healthcare industry which manufactures and distributes ultrasound probe disinfectors and other related technologies. It has offices in Australia, the U.S. and Canada, the United Kingdom and Europe,[2] employing more than 300 people.[3]
The company’s Trophon is the product used to reduce the spread of Healthcare Acquired Infections (HAIs). Its Trophon2 product includes AcuTrace technology, which enables digital record keeping and provides workflows for ultrasound probe high level disinfection.[4]
- ^ a b c d "NAN Report 2020" (PDF).
- ^ "The Nanosonics Story". www.nanosonics.com.au. Retrieved 31 May 2021.
- ^ "Nanosonics Ltd, NAN:ASX profile - FT.com". markets.ft.com. Retrieved 31 May 2021.
- ^ "Nanosonics Ltd, NAN:ASX profile - Reuters". Reuters. Retrieved 31 May 2021.